Send to

Choose Destination
Parasite. 2019;26:63. doi: 10.1051/parasite/2019063. Epub 2019 Nov 5.

Assessment of the insecticidal activity of oral afoxolaner against Phlebotomus perniciosus in dogs.

Author information

Boehringer Ingelheim Animal Health, 29 avenue Tony Garnier, 69007 Lyon, France.
Clinvet, Douar Dbabej Beni Yekhlef, 28815 Mohammedia, Morocco.


in English, French

Twelve healthy dogs were included in this laboratory efficacy study. Six dogs were randomly allocated based on body weight to an untreated control group and six to an afoxolaner (NexGard®) treated group. In the treatment group, afoxolaner was administered orally on Day 0 in accordance with label instructions. On Days 1, 14 and 28, each dog was exposed to 60 unfed female and 10 male Phlebotomus perniciosus sandflies for 1 h. At the end of each exposure period, sandflies were counted and assessed for viability and feeding status. There was no statistical difference in mortality (0.0-5.4%), nor in feeding proportion (61.6-78%) between the control and the treated groups at all 1-h post-exposure assessments. After collection, live fed and unfed sandflies were kept for viability assessments at 48 and 72 h post-exposure. In the untreated control group, the average percentages of live, fed, female sandflies after exposure, on Days 1, 14 and 28, ranged from 51% to 74% at 48 h and from 46% to 57% at 72 h, demonstrating model robustness over the 28 days of the study. Significantly fewer live fed sandflies were recorded for the afoxolaner treated group (p < 0.01). The insecticidal efficacy was 100%, 95.9% and 75.2% at 48 h post Days 1, 14 and 28 exposures, respectively, and 100%, 100% and 86.3% at 72 h post Days 1, 14, and 28 exposures, respectively. A single administration of oral afoxolaner (NexGard®) to dogs significantly killed P. perniciosus sandflies 48 and 72 h after blood feeding for 1 month.


Afoxolaner; Dog; Insecticide; NexGard®; Phlebotomus perniciosus; Sandfly

Supplemental Content

Full text links

Icon for EDP Sciences Icon for PubMed Central
Loading ...
Support Center